On today’s Stop Trading segment on CNBC, Jim Cramer said he was shocked that Revlimid from Celgene (CELG) was hardly noticed and he thinks it’s ready to run here. This down move in Celgene is a mistake. He’s sticking with his Onyx Pharmaceuticals Inc. (ONXX) after they gave positive data at the American Society of Clinical Onclogy ("ASCO") after the company extended the life of liver cancer patients.
Cramer said he’d still buy Wal-Mart (WMT-NYSE) here even after the run from the news Friday and after the upgrades today.
Jon C. Ogg June 4, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Smart Investors Are Quietly Loading Up on These “Dividend Legends”
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.
There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside.
If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
